Amneal Reports Fourth Quarter and Full Year 2021 Financial R

‒ Q4 2021 Net Revenue of $537 million; GAAP Net Loss of $6 million; Diluted Loss per Share of $0.04 ‒‒ Q4 2021 Adjusted Net Income of $54 million (1), Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.18 ‒‒ Full Year Net Revenue of $2.1 billion; GAAP Net Income of $11 million; Diluted EPS of $0.07...

Related Keywords

United States , America , Chintu Patel , Exchange Commission , Amneal Group , Drug Administration , Amneal Pharmaceuticals Inc , Diluted Loss , Net Income , Adjusted Diluted , Full Year Net Revenue , Full Year , Amneal Pharmaceuticals , Co Chief Executive , Eastern Time , Investor Relations , Securities Litigation Reform Act , Common Stock , Annual Report , Ended December ,